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Molecular targeting of cancer stem cells (CSCs) has
therapeutic potential for efficient treatment of
cancer, although relatively few specific targets have
been identified so far. Hypoxia-inducible factor
(HIF) was recently shown to regulate the tumorigenic
capacity of glioma stem cells under hypoxic condi-
tions. Surprisingly, we found that, under normoxia,
HIF1a signaling was selectively activated in the
stem cells of mouse lymphoma and human acute
myeloid leukemia (AML).HIF1a shRNA and HIF inhib-
itors abrogated the colony-forming unit (cfu) activity
of mouse lymphoma and human AML CSCs. Impor-
tantly, the HIF-inhibitor echinomycin efficiently
eradicated mouse lymphoma and serially transplant-
able human AML in xenogeneic models by preferen-
tial elimination of CSCs. Hif1a maintains mouse
lymphoma CSCs by repressing a negative feedback
loop in the Notch pathway. Taken together, our
results demonstrate an essential function of Hif1a-
Notch interaction in maintaining CSCs and provide
an effective approach to target CSCs for therapy of
hematological malignancies.
INTRODUCTION
Many human cancers contain cancer stem cells (CSCs) that are
responsible for initiating and maintaining tumor growth and
resistance to therapy (Al-Hajj et al., 2003; Bao et al., 2006;
Ishikawa et al., 2007; Lapidot et al., 1994; Li et al., 2007; Reya
et al., 2001; Singh et al., 2004). Understanding the mechanism
of self-renewal of CSCs is therefore not only crucial for under-
standing the fundamental cancer biology, but also for providing
new approaches for long-lasting cancer therapy (Wicha et al.,
2006). Similar to that of normal stem cells, CSC function involves
two related processes. First, the stem cells must undergo prolif-
eration (or self-renewal) to regenerate themselves. This process
involves Wnt, Hedgehog, and Bmi-1 (Beachy et al., 2004;
Lessard and Sauvageau, 2003; Molofsky et al., 2003; Parket al., 2003). Second, the cancer stem cells must survive
throughout tumorigenesis (Naka et al., 2010). For cancer
therapy, it is best to eliminate CSCs, as the dormant CSCs
may re-enter proliferative phase once the proliferation-inhibiting
drugs are cleared.
Hypoxia-inducible factors (HIFs) mediate the cellular response
to hypoxia. Keith and Simon (2007) proposed that a hypoxic
environment is required for cancer stem cell function. In support
of this notion, Li et al. (2009) showed that HIF2a, but not HIF1a,
was induced during hypoxia and was critical for the tumorige-
nicity of glioma stem cells. Since this mechanism operates
only under hypoxia, it is unclear whether it mediates the function
of CSCs in hematological malignancies. Here we report that an
HIF1a-Notch pathway is essential for maintenance of CSCs in
hematological malignancies under normoxia and can be
targeted to selectively eliminate CSCs.
RESULTS
Essential Role for HIF1a Activity in the Maintenance
of CSCs in Hematological Malignancies
We have recently reported that 100% of the transgenic mice
(TGB) with insertional mutation of the Epm2a gene succumbed
to lymphoma (Wang et al., 2006). In our search for the expression
of potential stem cell markers in the TGB lymphoma cells, we
found that a small subset of cells expressed both c-Kit and
Sca-1. To test if these cells had CSC activity, lymphoma cells
from the spleens of tumor-bearing TGB transgenic mice were
sorted based on expression of both c-Kit and Sca-1. We found
that this subset represented the self-renewing population among
the TGB lymphoma as determined by the colony-forming units
(cfu) assay (see Figure S1, available online). To determine if the
c-Kit+Sca-1+ cells are also the lymphoma-initiating cells
in vivo, we injected either c-Kit+Sca-1+ cells or c-KitSca-1
cells intraperitoneally (i.p.) into the syngeneic B10.BR mice. As
shown in Table 1, expt. 1, 3/3 mice that received 102 c-Kit+
Sca-1+ cells developed lymphomas usually within 10weeks after
injection, while none of the recipients of 104 of c-KitSca-1 cells
developed lymphoma even after 40 weeks of observation.
Similar results were obtained when the experiments were
repeated by intravenous injection (Table 1, expt. 2). The
lymphomas are characterized by an enlarged spleen (Figure S1)
and lymph nodes and metastases to the liver and lungs, but notCell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc. 399
Table 1. Identification of CSC Using c-Kit and Sca-1 Markers
Number of Cells Injected
Experiments Donor Recipient 10,000 1000 500 100
1 c-Kit+Sca-1+ B10.BR - - 3/3 3/3
c-KitSca-1 B10.BR 0/3 - - -
2 c-Kit+Sca-1+ B10.BR - - 4/4 3/3
c-KitSca-1 B10.BR 0/3 - 0/3 -
3 c-Kit+Sca-1+ B10.BR - - 5/5 5/5
c-KitSca-1 B10.BR 1/5 0/5 - -
4 c-Kit+Sca-1+ RAG2/ - - 5/5 5/5
c-KitSca-1 RAG2/ 1/5 0/5 - -
5 serial transplantation
Round 1 c-Kit+Sca-1+ B10.BR - - 3/3 3/3
c-KitSca-1 B10.BR 1/3 0/3 - -
Round 2 c-Kit+Sca-1+ B10.BR - - - 5/5
c-KitSca-1 B10.BR 2/5 - - -
Round 3 c-Kit+Sca-1+ B10.BR - - - 3/3
c-KitSca-1 B10.BR 0/3 (5000 cells/mouse) - -
The donor cells were isolated ex vivo from lymphoma (expts. 1 and 2) or cells that were cultured for more than 30 passages in vitro (expts. 3 and 4). The
routes of injection were intraperitoneal (i.p.) for experiments 1, 3, and 4, and intravenous for experiment 2. There was no tumor growth (0/3) when
10 c-Kit+Sca-1+ cells were transplanted into B10.BR mice. In experiment 5, donor cells were isolated ex vivo from lymphoma and injected i.p. The
lymphoma cells obtained in the first round were sorted and injected for the second around, then harvested, resorted, and injected for the third round.
The tumor-free mice were observed for 22–40 weeks to confirm the lack of tumor growth. (-) means no cells injected.
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HIF1a and Maintenance of Cancer Stem Cellsthe thymus (data not shown), unlike the spontaneously devel-
oped lymphoma that first appeared as a thymoma and then
metastasized into other organs (Wang et al., 2006). Furthermore,
no constitution of other cell lineages was achieved from the
c-Kit+Sca-1+ subset isolated from the tumors, which indicates
that the c-Kit+Sca-1+ cells are not the tumor-infiltrating hemato-
poietic stem cells (HSCs). In three rounds of serial transplanta-
tion (Table 1, expt. 5), the c-Kit+Sca-1+ cells, but not the
c-KitSca-1 cells, gave rise to lymphoma at a comparable
potency. Moreover, in each round of serial transplantation, the
c-Kit+Sca-1+ cells gave rise to all subsets of tumor cells,
including c-KitSca-1, c-Kit+Sca-1, and c-KitSca-1+
subsets (Figure S2A). The tumors maintained expression of
T cell marker CD8, but gradually lost cell surface expression
of the transgenic TCR (Figures S1 and S2). The significance of
the phenotypic shift is unclear. More importantly, the frequency
of the c-Kit+Sca-1+ cells remained around 1% throughout the
serial transplantation (Figure S2). Thus, there are self-renewing,
tumor-initiating cells among the c-Kit+Sca-1+ tumor cells.
Using the medium for assaying cfu of hematopoeitic progen-
itor cells, we were able to establish long-term cultures of the
TGB lymphoma cells. In over 30 passages, the c-Kit+Sca-1+ cells
remained at about 0.5%–1.5% of total lymphoma cell population
and maintained the cfu in vitro (data not shown) and tumor initi-
ation in vivo (Table 1, expts. 3 and 4), with an undiminished
efficiency. As demonstrated in Figure S2, the c-Kit+Sca-1+ cells
remained at a low percentage.
Using cfu as a surrogate assay, we set out to identify the
molecular program responsible for this activity. As shown in Fig-
ure 1A, treatment with pharmacologically effective doses of
Ly294002 (inhibitor of PI-3 kinase-AKT signal pathway), Rapa-
mycin (mTor-S6K protein synthesis pathway), SB216763400 Cell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc.(GSK3b-beta-catenin pathway inhibitor), Go¨6983 (PKC inhibitor),
2-DG (hexokinase inhibitor), H89 (PKA-CREB), PDTC (NF-kB
signal pathway), PD98059, SB203580, and SP600126 (MAPK
family ERK, p38, and JNK inhibitors, respectively) had no effect
on cfu. In contrast, low doses of HIF1a inhibitor echinomycin
(Kong et al., 2005a) abrogated the cfu.
In order to monitor the HIF1a activity of the CSCs, we estab-
lished a lentiviral reporter consisting of triple HIF-responsive
elements (HREs) in the upstream of a minimum TATA-box
sequence and an enhanced green fluorescence protein (EGFP)
cDNA, as shown in Figure S3A. A pause sequence was intro-
duced to eliminate LTR-promoter activity. To validate the
reporter, we first transiently transfected the HEK293 cells with
either the control vector or a mutant HIF1a (P402A/P564A)
cDNA in conjunction with either WT or mutant HRE-driven
EGFP reporters. The mutations made HIF1a functional under
normoxia conditions by resisting prolyl hydroxylation-mediated
degradation (Pereira et al., 2003). As expected, the HRE-EGFP
reporter was specifically induced byHIF1a but not by the control
vector. In contrast, the mutant HRE-EGFP reporter did not
respond to HIF1a (Figure S3A). Using this lentiviral vector, we
determined the effect of echinomycin on the percentage of cells
with HIF activity. As shown in Figure 1B, lower panel, a distinct
GFP+ population of cells that expressed both c-Kit and Sca-1
markers was found among in vitro-propagated lymphoma cells
(Figure 1B and Figure S3). The expression of GFP reflected HIF
activity, as it can be abrogated by mutation of the HREs
(Figure 1B, upper panel). We further tested the sensitivity of
this subset to echinomycin. As shown in Figure 1B, lower panel,
echinomycin abrogated the CSCs with an IC50 of 29.4 pM, which
is considerablymore sensitive than other cell types, where IC50 is
in the nM range (Kong et al., 2005b).
Figure 1. Lymphoma CSCs Were Abrogated by Selecting an HIF Inhibitor
(A) Selective ablation of lymphoma cfu by echinomycin. The cultured lymphoma cells were treated with given doses of pharmacologically effective drugs in
medium for 24 hr prior to cfu assay. Data shown are means ± SD of triplicates and have been confirmed by three independent experiments.
(B) Constitutive HIF activity among c-Kit+ cells and its sensitivity to echinomycin. The FACS profiles in the upper andmiddle panels show the specificity of theGFP
reporter by coexpression of GFP-expressing cells and c-Kit inWTHRE, but not mutant HRE lentiviral reporters. The dose response to inhibition by echinomycin is
shown in the bottom panel. The lymphoma cells transfected with the HRE reporter system were cultured in the presence of different concentrations of
echinomycin for 12 hr and the percentage of c-Kit+GFP+ cells was normalized against the untreated group (1.13%, which was defined as 100%). The dose that
resulted in 50% reduction of the c-Kit+GFP+ cells is defined as IC50.
A detailed description of the reporter and its specificity is presented in Figure S3A.
(C) Selectivity of HIF inhibitor for cfu of lymphoma CSCs over the cfu from hematopoietic progenitor cells (HPCs). c-Kit+Sca-1+ cells from either TGB or normal
bone marrow were treated with a given concentration of echinomycin overnight prior to cfu assay. The data shown were percentages of untreated controls and
were means ± SD of triplicates.
(D) ShRNA-silencing of Hif1a reduces susceptibility of cfu activity to echinomycin. Lymphoma cells were transduced three times with either scrambled vector or
Hif1a shRNA vector and were tested for their response to inhibition by echinomycin. Note that the shRNA groups yielded much-reduced numbers of cfu activity.
For better comparison, cfu activity in the groups that received no echinomycin treatment is defined as 100%. In the shRNA group, 100% is defined as 88 (sh1) and
132 (sh2) cfu per 200,000 cells. In the control group, 100% = 448 cfu per 200,000 cells.
(E) Echinomycin selectively induces apoptosis of CSCs. The cultured lymphoma cells were treated with 20 pM echinomycin or vehicle in medium for 16 hr. The
treated cells were stained with c-Kit and Sca-1, followed by staining with Annexin V.
(F) Therapeutic effect of a low dose of echinomycin. Cultured lymphoma cells (13 106/mouse) were injected i.p. into immune-competent B10.BRmice. Fourteen
days later, 10 mg/Kg/injection of echinomycin was injected at a 2-day interval for a total of five times. Control mice received vehicle only. The mice were observed
daily for survival. Data shown are representative of two to three independent experiments.
See Figures S1 and S2 for characterization of CSCs, Figure S3 for reporter of HIF activity, and HIF activity of in vitro-propagated and spontaneous lymphoma.
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cells were also present in ex vivo tumor cells (Figure S1). Since
the c-Kit+Sca-1 subset also has significant HIF activity (Fig-
ure S3B), it remains possible that the subset may also have
CSC activity. However, c-Kit+Sca-1 and c-KitSca-1+ cells
disappeared over time during in vitro culture (see Figure 1E
and Figure S3C, for examples). Since their disappearance did
not cause loss of CSC activity and since c-Kit+Sca-1 and
c-KitSca-1+ cells are progenies of the c-Kit+Sca-1+ cells, wehave decided to focus on the c-Kit+Sca-1+ population for our
subsequent analyses ofmolecular programming and therapeutic
elimination of CSCs.
To substantiate the role of HIF activity in CSC function, we
tested the effect of HIF inhibitors for both cfu in vitro and
tumor-initiating activity in vivo. Since the cfu from the lymphoma
CSCs and normal hematopoeitic progenitor cells (HPCs) can be
assayed under similar conditions, we tested the selectivity of
echinomycin for HPCs versus lymphoma CSCs. As shown inCell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc. 401
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HIF1a and Maintenance of Cancer Stem CellsFigure 1C, lymphoma CSCs were approximately 100-fold more
sensitive to echinomycin than HPCs.
Although echinomycin is also known to inhibit c-Myc activity,
its IC50 is in the nM range (Vlaminck et al., 2007). As shown in
Figure S4A, in the ranges used in this study, echinomycin
strongly inhibited HIF1a but had no effect on c-Myc function.
We also predicted that if echinomycin targets Hif1a, knock-
down of the Hif1a should convey resistance to the drug. To
test this hypothesis, we tested the impact of shRNA silencing
of the Hif1a gene on the susceptibility of cfu activity to echino-
mycin. Since the shRNA also reduced the cfu (see below), we
normalized the cfu in the untreated groups to 100%. As shown
in Figure 1D, silencing Hif1a reduced the sensitivity of cfu to
echinomycin. The apparent ‘‘synthetic lethality’’ provides
strong genetic evidence that Hif1a is the major target of
echinomycin.
To test if HIF activity was selectively required for survival of the
c-Kit+Sca-1+ CSC, we treated the tumor cell culture with low
doses of echinomycin (20 pM) for 16 hr and analyzed the
percentage of apoptotic c-Kit+Sca-1+ and c-KitSca-1
tumor cells. In the vehicle-treated group, approximately 1.8%
of c-Kit+Sca-1+ and c-KitSca-1 tumor cells bound to Annexin
V. Echinomycin increased Annexin V+ cells in the c-Kit+Sca-1+
tumor cells 6-fold, to about 10%. No effect was observed in
the c-KitSca-1 tumor cells (Figure 1E).
We injected 1 3 106 of cultured lymphoma cells i.p. into
immune-competent B10.BR mice. Four or 14 days later, the
mice that received lymphoma cells were either treated with
vehicle-only or three (Figure S4B) or five (Figure 1F) injections
of 10 mg/Kg/injection/mouse of echinomycin at 2-day intervals.
As shown in Figure 1F and Figure S4B, the untreated mice
survived only 6–10weeks, while all treatedmice lived until eutha-
nasia at 134 or 252 days after tumor-cell injection, with no sign of
tumor development upon necropsy. Two other known HIF
inhibitors, 2-methoxyestradiol (Mabjeesh et al., 2003) and
Geldanamycin (Minet et al., 1999), also reduced both cfu and
tumor initiation of CSCs, albeit at less efficacy (Figures S4C
and S4D). The difference in efficacy may be due to different
mechanisms of action and bioavailability. The therapeutic effi-
cacy of these HIF inhibitors demonstrated that HIFs may serve
as an effective therapeutic target.
To determine the molecular mechanism for the high
HIF activity in the CSCs, we sorted the lymphoma cells into
c-Kit+Sca-1+ or c-KitSca-1 subsets and analyzed HIF1a,
HIF2a, and HIF3a expression by RT-PCR. As illustrated in Fig-
ure 2A and quantitated in Figure 2B, c-Kit+Sca-1+ cells ex-
pressed Hif1a at a level that was 4-fold higher than the
c-KitSca-1 cells. No expression of Hif2a or Hif3a was
detected in the c-Kit+Sca-1+ cells. Consistent with higher levels
of HIF activity, expression of glucose transporters Glut1 and
c-myc, two known target genes of Hif1a, was also highly
elevated in the c-Kit+Sca-1+ cells (Figures 2A and 2B). In
contrast, no upregulation of Hif1a and Glut1 was observed
in the c-Kit+Sca-1+ bone marrow cells. An increased accumula-
tion of the Hif1a protein was also observed in the c-Kit+ cells in
comparison to the c-Kit cells (Figure 2C).
To establish the significance of Hif1a upregulation in the
c-Kit+Sca-1+ cells, we first used lentiviruses expressing Hif1a
shRNA to transduce the lymphoma cells. We used GFP to track402 Cell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc.cells expressing the lentiviral vector. As shown in Figure 2D, in
the vector control group with scrambled shRNA, equal numbers
of c-Kit+Sca-1+ cells were found in GFPhi and GFPlo subsets.
In contrast, in two shRNA-transduced tumors, the GFPhi popula-
tion was essentially devoid of the c-Kit+Sca-1+ cells, which indi-
cated that the silencing of Hif1a eliminated the c-Kit+Sca-1+
subset. Since more than a 50-fold reduction of CSCs was
observed on day 3 after transduction, we concluded that HIF
activity is required for themaintenance of the c-Kit+Sca-1+CSCs.
Consistent with this notion, after drug selection to enrich the
transduced cells, the colony formation assay revealed a 70%–
80% reduction in the Hif1a shRNA-transduced cells (Figure 2E).
The defects caused by the Hif1a shRNA were complemented by
transduction with human HIF1a cDNA, which is not targeted by
the Hif1a shRNA-1 (Figure 2F). Therefore, the observed defects
were not due to off-target effects of shRNA. To test the role for
Hif1a in tumor-initiating activity, we transplanted the control
vector (with scrambled shRNA) or Hif1a shRNA (either sh1 or
sh2)-transduced tumor cells into B10.BRmice after three rounds
of transduction. As shown in Figure 2G, transduction with Hif1a
shRNA (either sh1 or sh2) significantly reduced tumor-initiating
activity as judged by the significant delay of tumor-related death.
However, since the transduction efficiency is approximately
70% (Figure S5), shRNA is less efficient than echinomycin in
treatment of lymphoma.
Since HIF1a is normally degraded under normoxia by
a VHL-dependent mechanism (Kondo et al., 2002; Maranchie
et al., 2002), we also tested the expression of Vhl in the CSCs.
Our data demonstrated that the Vhl transcript was undetectable
in c-Kit+Sca-1+ cells, although significant levels were found in
the c-KitSca-1 subset (Figure 3A). To determine the signifi-
cance of Vhl downregulation, the tumor cells were infected
with Vhl-expressing lentivirus that also expresses GFP. To test
the impact of Vhl expression on the number of CSC, the GFPhi
and GFPlo subsets were compared for the abundance of
the c-Kit+Sca-1+ subset. The GFPhi subset contained no
c-Kit+Sca-1+ cells (Figure 3B). Thus, high Vhl expression ablated
the c-Kit+Sca-1+ cells. Consistent with this, the ectopic expres-
sion ofVhl significantly reduced the colony-forming activity of the
tumor cells (Figure 3C). To test the role of reduced Vhl in tumor-
initiating activity, we transplanted vector and Vhl cDNA-trans-
duced tumor cells into B10.BR mice. As shown in Figure 3D,
transduction with lentivirus-expressing Vhl cDNA significantly
reduced tumor-initiating activity as judged by the onset of
tumor-related death of the recipients. Taken together, our data
presented in Figures 2 and 3 demonstrate that both overexpres-
sion of Hif1a and reduction in Vhl are essential for CSC activity.
HIF Acts in Concert with the Notch Pathway
in Self-Renewal of CSCs
In order to determine the underlying molecular mechanisms by
which Hif1a activation promotes self-renewal of CSCs, we
examined the potential involvement of Wnt and Notch pathways.
Despite activation of the Wnt signaling in the TGB tumor (Wang
et al., 2006), our data demonstrated that the dominant-negative
Tcf-1, which we showed to inhibit tumor growth associated
with Epm2a downregulation (Wang et al., 2006), does not affect
the cfu of the TGB CSCs (data not shown). In contrast, g-secre-
tase inhibitor, L-685458, an inhibitor of the Notch pathway,
Figure 2. Constitutively Active HIF1a is Essential for Maintenance of CSCs
(A and B) Gene expression. The cultured lymphoma cells were sorted by BD FACSAria sorting system into c-Kit+Sca-1+ or c-KitSca-1 fractions. The transcripts
ofHif1a,Hif2a,Hif3a, Vhl,Glut1, and control gene bactinwere determined by RT-PCR. (A) Photograph of RT-PCR products. (B) Relative expression as measured
by real-time PCR. Relative expression ofHif1a,Glut1, and c-myc transcripts in FACS sorted c-Kit+Sca-1+ cells from either TGB tumor (Spl-tumor) or bonemarrow
(BM). The expression levels were expressed as fractions of housekeeping gene, bactin.
(C) Selective accumulation of Hif1a protein in the c-Kit+ but not c-Kit TGB tumor cells, as determined by western blot. The c-Kit+ (purity 83%) and c-Kit (purity
99%) subsets were purified by MAC beads and lysed for western blot.
(D) Silencing Hif1a abrogates the c-Kit+Sca-1+ CSC. TGB tumor cells were infected with either lentiviral vector with scrambled shRNA or lentiviral vector
expressing two independent shRNA (sh1 or sh2). Three days after infection, the bulk tumor cells were analyzed by flow cytometry. The GFPhi andGFPlo cells were
gated and analyzed for expression of c-Kit and Sca-1.
(E)Hif1a shRNA reduces cfu. The cultured lymphoma cells were infected with either lentiviralHif1a shRNA or scrambled shRNA by spinoculation, and the infected
cells were selected with 5 mg/ml of blasticidin for 1 week. The infected cells were seeded into 1% of methylcellulose culture medium at the density of 23 105/well.
The colony numbers were counted under amicroscope. Data shown aremeans ± SD of colony numbers in triplicates and are representative of three independent
experiments.
(F) Complementation of shRNA-induced defects by humanHIF1A cDNA. TGB tumor cells were transduced with either lentiviral vector control or vector encoding
human HIF1a protein. After blasticidin selection, the cells were transduced with lentiviral vector delivering either scrambled shRNA or Hif1a shRNA-1 that does
not match with human HIF1A. The cfu derived from transduced cells were counted based on expression of EGFP.
(G) Hif1a shRNAs abrogate tumor-initiating activity. TGB tumor cells were infected three times with lentiviral-expressing scrambled shRNA or Hif1a shRNA and
then injected into B10.BRmice (93 105/mouse, i.p.). The survival of the recipient mice (n = 5) was compared by Kaplan-Meier analysis. All mice that succumbed
had developed lymphoma as confirmed by necropsy. All data presented in this figure have been repeated at least twice.
See Figure S5 for lentiviral transduction efficacy.
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Notch signaling is overactivated in the CSCs, we sorted the
c-Kit+Sca-1+ cells and compared them with the bulk
c-KitSca-1 cells for expression of the Notch target gene
Hes1. As shown in Figure 4B, sorted CSCs had an approximately
3.5-fold increase in expression of Hes1. To determine whether
the increased Notch activation relates to Notch mutations, we
randomly selected five TGB tumors and sequenced the exons26, 27, and 34, which have shown to be the most frequent muta-
tions in T cell lymphoma. Since no mutations were detected,
Notch mutation is not responsible for elevated Notch activity in
the TGB CSCs.
In order to test whether the increased Notch activity depended
on HIF activity, we used three different HIF inhibitors to block
the upregulation of Notch targets in total TGB lymphoma cells
and CSCs enriched for c-Kit+ cells. The data in Figure 4CCell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc. 403
Figure 3. Downregulation of the Vhl Gene is Essential for Maintenance of CSCs
(A) Downregulation of Vhl transcript in c-Kit+Sca-1+ cells. The c-Kit+Sca-1+ and c-KitSca-1 subsets from thymomas, sorted as described in Figure S1, were
used as sources of RNA to analyze the levels of Vhl transcripts by real-time PCR.
(B) Ectopic expression of Vhl-ablated CSCs. TGB tumor cells were infectedwith either lentiviral vector control or lentiviral vector expressing Vhl cDNA. Three days
after infection, the bulk tumor cells were analyzed by flow cytometry. The GFPhi and GFPlo cells were gated and analyzed for expression of c-Kit and Sca-1.
(C) Vhl expression reduces tumor cfu. The cultured lymphoma cells were infected with either lentiviral Vhl cDNA or vector by spinoculation, and the infected cells
were selected with 5 mg/ml of blasticidin for 1 week. The transduced cells were seeded into 1%ofmethylcellulose culturemedium at a density of 23 105/well. The
colony numbers were counted under a microscope. Data shown are means ± SD of colony numbers in triplicate and are representative of three independent
experiments.
(D) Ectopic expression of Vhl cDNA inhibits tumor-initiating activity. TGB tumor cells were infected three times with lentiviral expressing vector alone or Vhl cDNA
and then injected into B10.BR mice (93 105/mouse, i.p.). The survival of the recipient mice (n = 5) was compared by Kaplan-Meier analysis. The development of
lymphoma was confirmed by necropsy. This experiment has been repeated twice.
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among the c-Kit+ CSCs. To validate the role of Hif1a, we tested
if knockdown of theHif1a reducedHes1 expression. As shown in
Figure 4D, compared with cells transduced with lentivirus
encoding the scrambled RNA, those transduced with Hif1a
shRNA had approximately 5-fold lower levels of Hes1
transcripts.
We analyzed expression of Notch1 to -4 in c-Kit+Sca-1+ and
c-KitSca-1 tumor cells. As shown in Figure S6A, Notch1 and
-2, but not Notch3 or -4, are expressed in the TGB tumor cells.
Since twoNotch genes are expressed, we searched for an effec-
tive dominant-negative mutant to suppress Notch signaling. By
trial and error, we identified a potent dominant-negative mutant
of Notch (aa 1955–2370), comprising intracellular domains of
Notch1 with truncation in both N and C termini. A nuclear local-
ization sequence (NLS) from SV40 virus was inserted in the N
terminus to facilitate its translocation into the nuclei. Based on
the structure of Notch I-C/CSL/Mastermind/DNA complex
(Wilson and Kovall, 2006), the deletion included both the DNA-
binding RAM domain and the four ankyrin repeats responsible
for binding the N terminus of Mastermind. As such, it is predicted
to act as a dominant-negative regulator of Notch signaling by
preventing the formation of Mastermind-CSL-Notch IC-DNA404 Cell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc.complex. We called the mutant dRdA1–4dOP (Figure 4E, left
panel). As shown in Figure 4E, right panel, transduction of the
dominant mutant resulted in about a 30-fold reduction of the
Hes1 transcripts. To substantiate the role for Notch signaling,
we transduced the TGB lymphoma with either control lentiviral
vector or that expressing dRdA1–4dOP. The transduced cells
were marked with GFP. As shown in Figure 4F, in the vector
control group, the percentages of c-Kit+Sca-1+ cells were
comparable in both GFPhi and GFPlo cells. In contrast, in the
dRdA1–4dOP-transduced group, more than a 5-fold reduction
in the percentage of c-Kit+Sca-1+ cells was observed in the
GFPhi subset. These data demonstrate that inactivation of the
Notch pathway prevents the survival of the c-Kit+Sca-1+ cells.
In serial plating experiments, transduction of dRdA1–4dOP
reduced self-renewal activity as revealed by cfu assay
(Figure 4G). Moreover, when the dRdA1–4dOP- or control
vector-transduced cells were transplanted into syngeneic
mice, it was clear that dRdA1–4dOP -transduction significantly
delayed the development of lymphoma, as demonstrated by
the survival analysis (Figure 4H).
Previous studies demonstrated that Hif1a may interact with
Notch directly to activate its target gene, Hey2, under hypoxia
conditions (Gustafsson et al., 2005). Using the reporter for
Figure 4. HIF Works in Concert with Notch Pathway to Maintain CSCs
(A) Inhibition of tumor cfu by Notch inhibitor L685458. The cultured lymphoma cells were treated with given doses of L685458 for 24 hr and subjected to cfu assay.
Data shown are means ± SD of triplicate samples and are representative of those of at least three independent experiments.
(B) Enhanced Notch activity in CSCs, as indicated by the levels of Hes1 transcripts. The lymphoma cells from spleens with TGB tumors were sorted into
c-Kit+Sca-1+ or c-KitSca-1 fractions. The expressions of Hes1 and mRNA in these two fractions were measured by real-time PCR.
(C) Inhibition of Notch activity by three distinct HIF inhibitors. Cultured TGB lymphoma cells were stained with APC conjugated anti-c-Kit antibody and enriched
twice using anti-APC coated MACS beads according to the manufacturer’s protocol (Militenyi Biotec). The c-kit positive cells-enriched samples (60.4% c-Kit+
cells) were treatedwith inhibitors of HIF for 16 hr. ThemRNA from the treated cells was extracted for PCR. Data shown aremeans ± SD of triplicates and represent
those from at least three independent experiments. 2ME2, 2-methoxyestradiol; GA, geldamycin.
(D) ShRNA silencing of Hif1a reduced expression of Hes1. TGB tumor cells were transduced with Hif1a shRNA. The transduced cells were selected with
blasticidin and were analyzed for Hif1a, Glut1, and Hes1 transcripts by real-time PCR.
(E–H) A critical role for Notch in maintenance of CSCs, as revealed by ectopic expression of Notch I-C dRdA1-42 dOP. (E) A truncated Notch gene with potent
dominant-negative activity in inhibiting the expression of Notch target gene Hes1. The upper left panel shows the diagram of the intracellular portion of Notch
protein, with the position of RAM, 7 ankyrin repeats (ANK1–7), transcriptional activation domain (TAD), C-terminal OPA (O), and PEST (P) sequence are marked.
The lower left panel shows the composition of the dRdA1–4dOP mutant-lacking RAM, ANK1–4, and C-terminal O and P sequence, but with insertion of nuclear
localization sequence (NLS). The right panel shows dominant inhibition of Hes expression. After three consecutive transductions by either vector control or the
dRdA1–4dOP mutant, the RNA were isolated and the transcripts of Hes1 measured by quantitative PCR. Data shown are means of triplicates and have been
reproduced by two independent experiments. (F) dRdA1–4dOP abrogates the c-Kit
+Sca-1+ subset. TGB tumor cells were infected with either lentiviral vector
control or lentiviral vector expressing dRdA1–4dOP. Three days after infection, the bulk tumor cells were analyzed by flow cytometry. The GFP
hi and GFPlo cells
were gated and analyzed for expression of c-Kit and Sca-1. (G) Notch IC- dRdA1-42 dOP reduces in vitro self-renewal activity of CSCs. The cultured lymphoma
cells were infected with either lentiviral vector encoding dRdA1–4dOP or vector control by three consecutive spinoculation. Data shown are the means ± SD of the
colony numbers in triplicate plates and are representative of those from at least three independent experiments. (H) dRdA1–4dOP abrogates tumor-initiating
activity. TGB tumor cells were infected three times with lentiviral expressing vector alone dRdA1–4dOP and then injected into B10.BR mice (13 10
6/mouse, i.p.).
The survival of the recipient mice was compared by Kaplan-Meier analysis with statistical significance determined by log-rank tests. All mice that died had
developed lymphomas. This experiment has been repeated twice.
See Figure S6A for expression of Notch1 and 2 in CSCs.
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enhancement of Notch signaling by the mutant HIF1a (P402A/
P564A) (Figures 5A and 5B). We therefore explored alternative
explanations for the function of Hif1a in Hes1 expression. It iswell established that, in response to Notch signaling, Hes1
expression is self-limiting and that the negative feedback
is mediated by Hes1 binding to the N-boxes in the Hes1 pro-
moter region (Hirata et al., 2002; Takebayashi et al., 1994).Cell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc. 405
Figure 5. Hif1a Inhibits Negative Feedback Regulation of Hes1 by Preventing Hes1 Binding to the N-boxes in the Hes1 Promoter
(A) Diagram of Hes1 promoter.
Detail sequence is provided in Figure S6B.
(B) Hif1a did not cooperate with Notch directly in activating Hes1 promoter. The Hes1 promoter sequence (225 to +65, TSS as +1) was linked to GFP and
transfected into 293 cells in conjunction with vector controls or vector containing cDNA encoding Hif1a (P402, 564 > A, called Hif1a-PA), Notch-IC cDNA, or
Notch-IC+ Hif1aPA. The promoter activity is measured by the green fluorescence intensity of transfected cells. Data shown were relative intensities. The intensity
of Hes1-GFP reporter is defined as 1.0. Transfection efficiency is normalized by cotransfected Renilla luciferase.
(C) Hif1a partially inhibited Hes1-mediated repression of the Hes1 promoter, as shown in (B), except the Hes1 or mutant Hif1a cDNA are used.
(D) Hif1a diminishes the negative auto-regulation of Hes1 expression in Notch signaling, as shown in (B), except different combinations of cDNAs were used.
Activity of Hes1 reporter in the absence of transfected Hes, Hif1a-PA, and Notch is defined as 1.0.
(E) Competitive inhibition between HIF1aPA and Hes1 in binding to Hes promoter, as revealed by ChIP. cDNAs encoding FLAG- or Myc-tagged Hes1 and
Hif1a-PA were transfected into 293 cells. Thirty-six hours after transfection, the transfectants were subject to ChIP analysis. Equal fractions of cells in each group
were used for western blot to confirm essentially identical levels of protein expression when cDNA encoding Hes1 and Hif1aPA were transfected alone or in
combination (data not shown). The data present are means ± SD (n = 3) of percentage of input DNA, as measured by real-time PCR using primers marked in
Figure S6B. Data shown are means+/SD of triplicates. The experiments have been repeated at least three times. Transfection was performed in a 24-well plate
for promoter assay or in a 6-well plate for ChIP assay. Total DNA amounts used for the transfection are 0.5 mg/per well of a 24-well plate and 1.5 mg/per well of
a 6-well plate.
See Figure S6B for promoter sequence of Hes1, with HRE, N-box, and primer sequences marked.
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nisch et al., 2001), we identified a bona fide HRE immediately
after each of the two critical N-boxes (Figure 5A and Figure S6B).
Given their proximity, we hypothesized that Hif1a may directly
inhibit autoregulation of Hes1. Indeed, transfection of Hes1
cDNA reduced the Hes1 promoter activity by about 10-fold.
This inhibition was partially reversed by the oxygen-resistant
HIF1a (Figure 5C). Likewise, in the presence of Notch IC
cDNA, Hes1 also repressed its own promoter (Figure 5D).
Hif1a reversed the repression in a dose-dependent manner (Fig-
ure 5D). Using chromatin immunoprecipitation (ChIP) (Figure 5E),
we observed significant binding of HIF1a to the region bound by406 Cell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc.Hes1. Interestingly, the HIF1a and Hes1 competed with each
other in binding to the region. Our data suggest that Hif1a
enhanced Notch-induced Hes1 expression by antagonizing the
autoregulation of the Hes1 gene.
Therapeutic Elimination of Leukemia Stem Cells
for AML
Based on these observations, we explored the therapeutic
potential of HIF inhibitors for human hematological malignan-
cies. Since theHIF function in lymphomaCSCswas independent
of a hypoxic environment, it is plausible that the same
pathway may also function in leukemia stem cells (LSCs).
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characterized, and the xenogeneic model had been established
to assay the AML-LSC function in vivo (Lapidot et al., 1994). The
classic studies by Dick and colleagues, using the NOD-SCID
model, demonstrated that the AML-LSC has a phenotype
of CD34+CD38 (Lapidot et al., 1994). To determine whether
the HIF1a gene is overexpressed in this subset, we sorted
the CD34+CD38, CD34+CD38+, CD34CD38, and the
CD34CD38+ subsets by FACS (Figure 6A) and analyzed
the expression of HIF1a and its target GLUT1. As shown in Fig-
ure 6B, the CD34+CD38 subset had the highest levels of
HIF1a transcript. Correspondingly, GLUT1 transcript is also
elevated in the CD38CD34+ cells. All six cases of AML tested
showed increased expressions of HIF1a and GLUT1 in the
CD38CD34+ subset (data not shown), which indicate that
increased HIF1a expression is a general feature of those cells
bearing markers of AML-LSCs. The HIF1a protein is also selec-
tively enriched in theCD38CD34+ subsets in comparison to that
in the CD38CD34 subset (Figure 6C).
TheCD34+CD38 are also known to formAMLcolonies in vitro
(Lapidot et al., 1994), which provides us with a simple assay to
test the significance of HIF1a. To determine the role for HIF1a
in cfu, we transduced AML with either scrambled or Hif1a
shRNA-2 that targets conserved sequences between mouse
and human HIF1a. Since the transduction efficiencies of both
scrambled and shRNA vector, as measured by GFP+% cells,
were comparable between scrambled and shRNA-silenced
samples (Figure 6D, legends), the function of the HIF1a gene
can be evaluated by the number of GFP+ colonies. As shown
in Figure 6D, in two independent AML samples tested, Hif1a
shRNA reduced by 60%–70%when compared to the scrambled
shRNA control. Moreover, HIF1a shRNA greatly reduced the
sensitivity of the cfu to echinomycin (Figure 6E). These data
demonstrated that echinomycin also target HIF1a in human
AML samples. To test the role for HIF1a in more clinical samples,
we tested seven independent cases (Table S1) for their cfu
sensitivity to echinomycin. As shown in Figure 6F, for all cases
tested, echinomycin inhibited colony formation with IC50
between 50 and 120 pM. These data, together with the specific
reduction of echinomycin sensitivity by HIF1a gene silencing
(Figure 6E), demonstrated a critical role for HIF1a in cfu activity
of the seven clinical AML samples. Given the fact that the AML
cases used have diverse genetic alterations (Table S1), the
broad inhibition by echinomycin is consistent with an important
function of HIF1a in AML-cfu, which include the CD34+CD38
AML-LSC.
Conventional cancer therapy appears to enrich cancer stem
cells (Baumann et al., 2008; Dean et al., 2005; Phillips et al.,
2006; Yu et al., 2007). An NFkB inhibitor, dimethylamino analog
of parthenolide, showed some selectivity for AML-LSC (Guzman
et al., 2007). Since the HIF1a activity appears to be selectively
activated in AML, we were intrigued by the possibility that
AML-LSCs can be targeted selectively by echinomycin. As
shown in Figure 6G, echinomycin was about 100-fold more effi-
cient in inducing apoptosis of the CD34+CD38 population, in
comparison to the dominant AML cells (CD34+CD38+ for most,
but CD34CD38+ for two AML cases).
To test whether echinomycin can be used as a potential ther-
apeutic agent for AML, we established a xenogeneic AMLmodelusing human AML samples. As shown in Figure S7, primary clin-
ical samples from AML patients reconstituted irradiated NOD-
SCID mice with immature human myeloid cells, characterized
by the expression of human CD45, CD11b, and CD33, but not
mature myeloid markers CD14, CD15, or B cell marker CD19.
Remarkably, a short-term treatment with echinomycin, starting
at 15 days after transplantation, completely eliminated human
cells from sample AML150 and dramatically reduced the burden
of human leukemia of AML71 (Figure 6H). The residual cells in
echinomycin-treated mice were not differentiated as judged by
the lack of mature myeloid markers CD14 and CD15 (Figure 6I).
The incomplete remission of AML71 also allowed us to eval-
uate if echinomycin selectively reduce the AML-LSC, using the
CD34+CD38 markers (Lapidot et al., 1994). Echinomycin
reduced percentages of CD34+CD38 cells in bone marrow by
more than 10-fold (Figure 6J, top panel). Even among the human
CD45+ compartment, the relative abundance of AML-LSCs was
also reduced (Figure 6J, lower panel). To substantiate the impact
of echinomycin on the leukemia-initiating cells, we carried out
serial transplantation studies to determine whether echinomycin
reduced self-renewal of AML-LSCs. As shown in Figure 6K, while
bone marrow from untreated mice induced leukemia in all new
recipients, bone marrow from echinomycin-treated mice failed
to do so in any recipients. Therefore, the residual cells in the
echinomycin-treated bone marrow are devoid of AML-LSCs.
DISCUSSION
We have used both in vitro cfu and in vivo tumor-initiating prop-
erties to characterize the molecular mechanism for self-renewal
of CSCs. Our screening of inhibitors for major signal transduction
pathways revealed a potent inhibition of cfu and tumorigenesis
by echinomycin, a known inhibitor of HIF (Kong et al., 2005a).
The specificity of HIF targeting by echinomycin is supported by
qualitatively similar effects of multiple HIF inhibitors and
a requirement of Hif1a expression for sensitivity to the drug.
Since the short-term treatment with echinomycin resulted in
a specific increase of apoptosis in the c-Kit+Sca-1+ cells, the
HIF1a is selectively required for survival of CSCs. The specificity
of Hif1a shRNA is confirmed by genetic complementation. Inter-
estingly, the increasedHIF activity is observed under normoxia in
CSCs of both leukemia and lymphoma. In the murine lymphoma,
CSC maintenance also depends on downregulation of Vhl,
which explains why the increased Hifa activity no longer
requires a hypoxic environment. In contrast, reported HIF func-
tion in glioma stem cells is strictly hypoxia dependent (Li et al.,
2009). The hypoxia-independent activation of HIF expands
the spectrum of cancer in which HIF can play a critical role in
pathogenesis.
In our effort to understand the molecular pathway responsible
for the maintenance of CSCs, we uncovered that Hif1a potenti-
ates the induction of Hes1 by Notch. Hes1 is an important Notch
target known to be critical for stem/progenitor cell functions
(Janzen et al., 2006; Tomita et al., 1999; Yu et al., 2006). In
contrast with the previous studies using Hey2 promoter as
readout (Gustafsson et al., 2005), we did not observe a direct
cooperation between Hif1a and Notch IC in the induction of
theHes1 gene. Rather, Hif1a blocks a negative feedback regula-
tion of Hes1 by preventing Hes1 from binding to the N-box ofCell Stem Cell 8, 399–411, April 8, 2011 ª2011 Elsevier Inc. 407
Figure 6. HIF1a is a Target for Therapeutic Elimination of Human AML in Xenogenic Mouse Model
(A) Isolation of four subsets of tumor cells in AML samples. Bone marrow cells from AML patient MI-AML71 were stained for CD34 and CD38 and sorted into four
subsets for RNA isolation. The presort samples and the gates used for sorting are shown in the left panel and the postsorted populations are shown in the middle
and right panels. The percentages of cells in each gate are provided in the panels.
(B) Expression of HIF1a (top) and GLUT1 in the subsets. Data shown are means ± SD of transcript levels of the genes, presented as percentages of b-actin from
the same samples. Enhanced expression in the CD34+CD38 samples have been observed in all six AML samples tested.
(C) Increased accumulation of HIF1a protein in CD34+CD38 AML cells. CD38+ cells were depleted by negative selection with anti-CD38-conjugated magnetic
beads. The remaining cells were further separated into CD38CD34+ (purity 72%–78%) andCD38CD34 (purity 96%–100%) cells by positive selection. Lysates
from the two populations were used for western blot.
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universal, role of Notch in maintenance of a variety of tissue
stem cells (Duncan et al., 2005; Fre et al., 2005; van Es et al.,
2005; Wilson and Radtke, 2006), our data suggest an important
functional conservation between CSCs and tissue stem cells.
In contrast to conventional chemotherapeutic drugs and
radiation therapy that appears to spare CSCs (Baumann et al.,
2008; Costello et al., 2000; Dean et al., 2005; Ishikawa et al.,
2007; Phillips et al., 2006; Yu et al., 2007), echinomycin selec-
tively eliminated CSCs and conveyed remarkable therapeutic
efficacy for leukemia and lymphoma. On a per-molar basis, echi-
nomycin is 10,000-fold more effective than what has been re-
ported for dimethylamino-parthenolide, which also showed
some selectivity for AML stem and progenitor cells (Guzman
et al., 2007). The long-lasting elimination of lymphoma CSCs is
demonstrated by a complete lack of recurrence in echinomy-
cin-treated mice. The high efficacy is shown by the fact that
less-effective therapy was achieved by as little as 200 ng of echi-
nomycin in vivo and pico molar range IC50 as measured by cfu
assay in vitro.
In the xenogeneic model of human AML, we observed that
short-term treatment by echinomycin prevented serial transplan-
tation of AML. These data, together with preferential induction of
apoptosis of CD34+CD38 cells in vitro as well as selective
reduction of CD34+CD38 cells within the hCD45+ cells, support
the notion that the drug preferentially targets AML stem cells. It is
worth noting that while the frequency of CD34+CD38 cells in
echinomycin-treated recipients is reduced 5-fold, there were still
approximately 2000 CD34+CD38 cells per inoculate for the
secondary recipients. As previous studies indicate, 1000–5000
cells are sufficient to initiate AML in the NOD-SCID model
(Bonnet and Dick, 1997). The fact that none of the five recipients
had detectable AML suggests that in addition to physical reduc-
tion of CD34+CD38 cells, echinomycin may also abrogate the
LSC activity of the remaining CD34+CD38 AML cells. Our(D) HIF1a activity is essential for AML-cfu. AML60 and AML71 were transduced wi
were counted based on EGFP signal. The transduction efficacy was measured by
AML60: Sr, 32.6%; Sh2: 32.48%; AML71: Sr, 45.70%; and Sh2: 40.19%. The sh
genes. Data showing are cfu per 2 3 105 cells.
(E) HIF1a silencing increased the resistance of cfu to echinomycin, as shown i
echinomycin. Data shownwere percentages of cfu after normalized to untreated g
Figure 6D. Data in (D) and (E) have been repeated once with the same conclusio
(F) AML-cfu in all seven AML samples are highly sensitive to echinomycin. AML s
were pretreated with given concentrations of echinomycin in 2 ml medium for 24
The colony numbers were counted 7–10 days later. The data shown are percent
(G) Echinomycin selectively eliminates the CD34+CD38 subset of AML cells. Prim
they were cultured with given doses of echinomycin or vehicle control for 30 hr
consisting of CSF, GM-CSF, and IL-3 at a density of 5 3 105/ml. The cells were s
DAPI. Data shown are the percentages of Annexin V+DAPI± cells with the specifie
subtracted. The filled symbols show the data for theCD34+CD38 subsets, while t
AML32, AML60, and AML71, and CD34CD38+ for AML15, AML36, and AML13
(H) Therapeutic effect of human AML in NOD-SCID mice, data shown are percent
40 days after last treatment. The therapeutic effect has been repeated twice.
(I) Echinomycin does not induce differentiation of AML cells in vivo, as revealed b
untreated groups. Data shown are profiles of CD14 and CD15 among human CD
(J) Selective depletion of the CD34+CD38 subset by echinomycin. Data shown
marrow, while the lower panel shows the subsets within human leukemia cells.
(K) Despite the presence of leukemia cells, bone marrow from echinomycin-treate
profiles are presented in the top panel, while the summary data from five mice p
See Figure S7 for the phenotype of AML cells in the xenogeneic model.approach complements other recent studies targeting CSCs
(Dierks et al., 2008; Ginestier et al., 2009; Jin et al., 2006; Zhao
et al., 2009), although these drugs have not been shown to target
the intrinsic survival program of CSCs. Since echinomycin is
a competitive inhibitor of HREs in multiple HIF target genes
(Kong et al., 2005a), it is theoretically more difficult to mutate
multiple target genes to develop resistance to echinomycin. In
contrast, resistance to an inhibitor of the Hedgehog pathway
appears to develop readily due to the mutation of Smoothened
(Yauch et al., 2009).
Selective targeting of cancer cells is key in reducing the side
effects of cancer therapy. Despite similarity between CSCs
and normal tissue stem cells, we showed that echinomycin
selectively inhibited the cfu of lymphoma CSCs without affecting
the cfu of HPCs of normal bone marrow in mice. Remarkably,
based per square meter of body surface, echinomycin, at doses
that are nearly 50-fold higher than what was used in this study,
was well-tolerated in human (Muss et al., 1990), although the
impact of the drug on CSCs was not evaluated because these
trials predated the re-emergence of CSC concept (Lapidot
et al., 1994). The remarkable efficacy of a previously abandoned
cancer drug demonstrates the need to test drugs based on the
concept of cancer stem cells (Diehn et al., 2009). The selective
targeting of CSCs validated a key prediction of the cancer
stem cell hypothesis; namely, identification of the cell-intrinsic
molecular program for CSC maintenance enables cancer eradi-
cation by elimination of CSCs (Park et al., 2009).
EXPERIMENTAL PROCEDURES
AML Samples
AML patients diagnosed at the University of Michigan Comprehensive Cancer
Center between 2005 and 2009 were enrolled in this study. The study was
approved by the University of Michigan Institutional Review Board. Written
informed consent was obtained from all patients prior to enrollment. We
used the same AML diagnostic criteria (R 20% myeloblasts in the boneth either scrambled (Sr) orHIF1a shRNA (Sh2). The cfu of transduced AML cells
FACS prior to plating. The percentages of GFP+ cells for the experiment were
RNA used, Sh2, targets shared sequences between mouse and human HIF1a
n (E), except the transduced cells were treated with given concentrations of
roup (defined as 100%). The number of colonies in the control group is shown in
ns.
amples (2.5 3 105/ml) from either peripheral blood (PB) or bone marrow (BM)
hr. Treated viable cells were then plated at 105/well for cfu assay in triplicates.
ages means ± SD of untreated controls.
ary AML samples were thawed from liquid nitrogen. After overnight recovery,
in RPMI 1640 containing 10% fetal calf serum and human cytokine cocktail
tained with antibodies against CD34, CD38 in conjunction with Annexin V, and
d markers. The Annexin V+ cells percentage in vehicle-treated group has been
he open symbols showdata for the bulk leukemia cells (CD34+CD38+ for AML9,
2). These data have been repeated twice.
ages of human CD45 (hCD45)+ cells in the bone marrow of the recipient mice at
y the lack of mature myeloid markers on the bulk of human cells in treated and
45+ cells.
in the top panels are the abundance of CD34+CD38 subsets in mouse bone
d mice failed to reinitiate leukemia in the new NOD-SCID mice. Representative
er group are presented in the lower panel.
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HIF1a and Maintenance of Cancer Stem Cellsmarrow or peripheral blood) and determined FAB subclassification through
review of both laboratory and pathology reports dated at the time of diagnosis
and interpreted by hematopathologists. Cytogenetic risk stratification was
determined according to SWOG/ECOG criteria (Slovak et al., 2000).
ShRNA-Mediated Knockdown of HIF1a and Ectopic
Expression of Vhl and dRdA1, 2 dOP
The lentiviral vector plenti6/V5-TOPO, obtained from Invitrogen, was modified
by replacing CMV promoter with U6 promoter to drive shRNA-expressing
cassette. This is followed by a pGK-driven EGFP cassette and a blasticidin-
resistant cassette. The core sequence of Hif1ashRNA-1 (Sh-1) is 50-CTAGA
GATGCAGCAAGATC-30, while that of Hif1ashRNA-2 (Sh-2) is 50-GAGAGA
AATGCTTACACAC-30. The T7-blasticidin cassette in the plenti6/V5-TOPO
vector was replaced with a PGK-GFP cassette to express full-length Vhl
cDNA and dominant-negative Notch mutant dRdA1-42 dOP (AA1995-2370)
in experiments that involved no drug selection. For those studies that involved
drug selection, we replaced the CMV promoter with a CMV-IRES-EGFP
cassette and cloned Vhl cDNA after the CMV promoter. The tumor cell cultures
were infected with either control lentivirus or lentivirus encoding Hif1a shRNA,
dRdA1-42 dOP, or Vhl cDNA by spinoculation. The cultures were selected with
5 mg/ml of blasticidin for 5 days to remove uninfected cells.
In Vitro Colony Formation Assay for AML, TGB Tumor Cells,
and Bone Marrow Cells
This was carried out as previously described (Wang et al., 2006).
In Vivo Tumorigenicity Assay-TGB
Given numbers of total tumor cells or sorted subsets were injected into either
immune-competent B10.BR mice or BALB Rag2//c mice. Moribund mice
were considered to have reached the experimental endpoint and were eutha-
nized. The therapeutic effects were analyzed by Kaplan-Meier survival
analysis.
Xenogeneic Tumor Model
NOD-SCID mice received 1.8 Gy of irradiation and i.v. injection with 83 106 of
peripheral blood cells from patients AML71 and AML150. Fifteen days later,
10 mg/kg/injection of echinomycin was injected daily for 5 consecutive days
followed by 2 days rest, and then the cycle was repeated once. Control
mice received vehicle only. Forty days later, the treated mice were sacrificed
and the BM cells were collected and stained with antibodies specific for
human (hCD45) and mouse leukocyte markers (mCD45) in conjunction with
CD34 and CD38 or with CD19, CD33, CD14, and CD15. In some experiments,
the vehicle or echinomycin-treated bone marrow cells from AML71-reconsti-
tuted mice were pooled and serially transplanted into new recipients (1.5 3
106 per mouse at 1 day after irradiation). The percentages of AML cells and
stem cells are presented in Figures 6H and 6J, respectively. The recipients
received no further treatment and were sacrificed at 8 weeks after transplan-
tation to analyze the reconstitution of human cells.
Statistics
Student t tests were used to determine significance of the difference between
two groups, while log-rank tests were used for survival analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
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